ro 15-0216 has been researched along with aclarubicin in 1 studies
Studies (ro 15-0216) | Trials (ro 15-0216) | Recent Studies (post-2010) (ro 15-0216) | Studies (aclarubicin) | Trials (aclarubicin) | Recent Studies (post-2010) (aclarubicin) |
---|---|---|---|---|---|
12 | 0 | 0 | 826 | 97 | 105 |
Protein | Taxonomy | ro 15-0216 (IC50) | aclarubicin (IC50) |
---|---|---|---|
72 kDa type IV collagenase | Homo sapiens (human) | 9.9 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.106 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alsner, J; Andersen, AH; Jensen, PB; Sinding, J; Sørensen, BS; Westergaard, O | 1 |
1 other study(ies) available for ro 15-0216 and aclarubicin
Article | Year |
---|---|
Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events.
Topics: Acetanilides; Aclarubicin; Amsacrine; Animals; Base Sequence; Cattle; DNA Topoisomerases, Type II; Molecular Sequence Data; Nitroimidazoles; Nucleic Acid Conformation; Nucleic Acid Hybridization; Oligodeoxyribonucleotides; Thymus Gland; Topoisomerase II Inhibitors; Trypanocidal Agents | 1992 |